Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 1

Status

Terminated 2Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 14Genitourinary 4Endocrine 4NET 2Gastrointestinal 2CNS 2Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Prostatic Neoplasms 1427Carcinoma, Renal Cell 587Urinary Bladder Neoplasms 368Kidney Neoplasms 257Carcinoma, Transitional Cell 190Neoplasm Metastasis 163Neoplasms 124Melanoma 83Breast Neoplasms 80Carcinoma, Non-Small-Cell Lung 78Testicular Neoplasms 67Ovarian Neoplasms 62Sarcoma 55Urethral Neoplasms 51Non-Muscle Invasive Bladder Neoplasms 51Wilms Tumor 49Lung Neoplasms 45Colorectal Neoplasms 44Uterine Cervical Neoplasms 39Neuroblastoma 39Penile Neoplasms 37Pancreatic Neoplasms 37Urologic Neoplasms 34Recurrence 32Lymphoma, Non-Hodgkin 32Ureteral Neoplasms 28Osteosarcoma 28Testicular Germ Cell Tumor 26Small Cell Lung Carcinoma 26Head and Neck Neoplasms 26

Interventions

pembrolizumab 1enzalutamide 1apalutamide 1abiraterone 1Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Small Cell × Genitourinary × Clear all
NCT05551117 2026-02-09

Tamarack

MacroGenics

Phase 2 Terminated
192 enrolled 20 charts
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

NCT04926181 2025-05-15

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
2 enrolled 12 charts
GenitourinaryThoracic

Prostatic Neoplasms, Carcinoma, Small Cell, Bulbo-Spinal Atrophy, X-Linked, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡